PRLD IPOs 9.57M* shares @$19.00: https://www.globenewswire.com/news-release/2020/09/25/2099070/0/en/Prelude-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. A rather generic description of an oncology company; more info is available in the S-1 filing, of course. *Assuming exercise of underwriter’s option.